Allurion Stock Triples on Plan to Test Gastric Balloon With Obesity Drugs
Key Takeaways Allurion Technologies said it planned to test its gastric balloon with the key ingredient in popular ...
Wall Street Breakfast Podcast: Allurion Soars On Balloon And GLP-1 Study Plans
Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...
Monthly Prescribing Reference21d
AUDACITY Trial: Weight Loss Observed With Allurion Intragastric Balloon
Topline data were announced from the AUDACITY trial evaluating the Allurion Gastric Balloon, a swallowable ... for people with obesity,” said Dr Shelby Sullivan, Professor of Medicine and ...
Allurion stock soars 70% on weight-loss therapy update
Allurion (ALUR) stock soared 70% after the company announced it is planning to conduct a clinical study of its gastric balloon weight-loss product in combination with GLP-1 drugs.
Nasdaq6d
Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program
The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-lessTM gastric balloon for weight loss, the Allurion ...